Movatterモバイル変換

[0]ホーム
URL:

IN2012DN06437A - - Google Patents

Info

Publication number
IN2012DN06437A
IN2012DN06437AIN6437DEN2012AIN2012DN06437AIN 2012DN06437 AIN2012DN06437 AIN 2012DN06437AIN 6437DEN2012 AIN6437DEN2012 AIN 6437DEN2012AIN 2012DN06437 AIN2012DN06437 AIN 2012DN06437A
Authority
IN
India
Prior art keywords
peptide
glucagon
gip agonist
combination
analog
Prior art date
Application number
Inventor
Richard D Dimarchi
Tao Mat
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech CorpfiledCriticalUniv Indiana Res & Tech Corp
Publication of IN2012DN06437ApublicationCriticalpatent/IN2012DN06437A/en

Links

Classifications

Landscapes

Abstract

Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments the peptide combination is provided as a composition e.g. a pharmaceutical composition while in other embodiments the peptide combination is provided as a kit. In yet other embodiments the peptide combination is provided as a conjugate e.g. a fusion peptide a heterodimer. In specific aspects the GIP agonist peptide is an analog of native human glucagon. In specific aspects the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Methods of treating a disease e.g. a metabolic disorder such as diabetes and obesity comprising administering the peptide compositions described herein are further provided.
IN6437DEN20122010-01-272011-01-26IN2012DN06437A (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US29881210P2010-01-272010-01-27
PCT/US2011/022608WO2011094337A1 (en)2010-01-272011-01-26Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity

Publications (1)

Publication NumberPublication Date
IN2012DN06437Atrue IN2012DN06437A (en)2015-10-09

Family

ID=44319749

Family Applications (1)

Application NumberTitlePriority DateFiling Date
IN6437DEN2012IN2012DN06437A (en)2010-01-272011-01-26

Country Status (11)

CountryLink
US (2)US8551946B2 (en)
EP (1)EP2528618A4 (en)
JP (2)JP2013518115A (en)
KR (1)KR20120123443A (en)
CN (1)CN102834108A (en)
BR (1)BR112012018585A2 (en)
CA (1)CA2788304A1 (en)
IN (1)IN2012DN06437A (en)
MX (1)MX2012008603A (en)
RU (1)RU2012136450A (en)
WO (1)WO2011094337A1 (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CA2628241C (en)2005-11-072016-02-02Indiana University Research And Technology CorporationGlucagon analogs exhibiting physiological solubility and stability
SG177953A1 (en)2007-01-052012-02-28Univ Indiana Res & Tech CorpGlucagon analogs exhibiting enhanced solubility in physiological ph buffers
KR20090119876A (en)2007-02-152009-11-20인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon / LPL-1 Receptor Co-Analyst
WO2009058662A2 (en)2007-10-302009-05-07Indiana University Research And Technology CorporationGlucagon antagonists
EP2214691B1 (en)2007-10-302015-09-30Indiana University Research and Technology CorporationCompounds exhibiting glucagon antagonist and glp-1 agonist activity
CL2009001424A1 (en)2008-06-172010-04-30Univ Indiana Res & Tech Corp Glucagon-like peptide; dimer comprising two of said peptides; pharmaceutical composition comprising it; and its use to treat diabetes or induce weight loss.
WO2009155257A1 (en)2008-06-172009-12-23Indiana University Research And Technology CorporationGlucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
PE20100056A1 (en)2008-06-172010-01-26Univ Indiana Res & Tech Corp GLUCAGON ANALOGS AS GIP AGONISTS
CN102325539A (en)2008-12-192012-01-18印第安纳大学研究及科技有限公司 Amide-based glucagon superfamily peptide prodrugs
PE20120914A1 (en)2009-06-162012-08-22Univ Indiana Res & Tech Corp GIP RECEIVER ACTIVE GLUCAGON COMPOUNDS
EA022816B1 (en)2009-07-132016-03-31Зилэнд Фарма А/СAcylated glucagon analogues
EP2512503A4 (en)2009-12-182013-08-21Univ Indiana Res & Tech Corp GLUCAGON / GLP-I RECEPTOR CO-AGONISTS
IN2012DN06437A (en)2010-01-272015-10-09Univ Indiana Res & Tech Corp
AR080592A1 (en)2010-03-262012-04-18Lilly Co Eli PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
RU2604067C2 (en)2010-05-132016-12-10Индиана Юниверсити Рисерч Энд Текнолоджи КорпорейшнGlucagon superfamily peptides exhibiting nuclear hormone receptor activity
MX2012013005A (en)2010-05-132013-02-26Univ Indiana Res & Tech CorpGlucagon superfamily peptides exhibiting g protein-coupled receptor activity.
JP2013540102A (en)2010-06-242013-10-31インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Peptide prodrugs of the glucagon superfamily modified via amide bonds
PH12013501215A1 (en)2010-12-222013-11-18Univ Indiana Res & Tech CorpGlucagon analogs exhibiting gip receptor activity
EP2654774A4 (en)2010-12-222015-07-01Marcadia Biotech IncMethods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US9453062B2 (en)2011-06-102016-09-27Beijing Hanmi Pharmaceutical Co., Ltd.Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
HRP20170890T1 (en)2011-06-222017-09-08Indiana University Research And Technology CorporationGlucagon/glp-1 receptor co-agonists
AU2012273365A1 (en)2011-06-222014-01-16Indiana University Research And Technology CorporationGlucagon/glp-1 receptor co-agonists
KR20140097151A (en)2011-11-172014-08-06인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
EA028665B1 (en)2012-05-032017-12-29Зилэнд Фарма А/СGip-glp-1 dual agonist compounds and methods
WO2013170636A1 (en)2012-05-182013-11-21爱德迪安（北京）生物技术有限公司Protein and protein conjugate for diabetes treatment, and applications thereof
WO2013186240A2 (en)2012-06-142013-12-19SanofiExendin-4 peptide analogues
BR112014031671A2 (en)2012-06-212018-08-07Hoffmann La Roche glucagon analogs exhibiting gip receptor activity
ES2602486T3 (en)2012-06-212017-02-21Indiana University Research And Technology Corporation Glucagon analogs showing GIP receptor activity
AR091476A1 (en)*2012-06-212015-02-04Univ Indiana Res & Tech Corp REGION FUSION POLYPEPTIDES Fc POLYPEPTIDE BINDING RECEIVER OF INCRETINA AND CONJUGADOS WITH EFECTIVE FUNCTION Fc ALTERED
EP2875043B1 (en)2012-07-232016-12-21Zealand Pharma A/SGlucagon analogues
TWI608013B (en)2012-09-172017-12-11西蘭製藥公司 Glucagon analog
UA116217C2 (en)2012-10-092018-02-26СанофіExendin-4 derivatives as dual glp1/glucagon agonists
PT2916819T (en)2012-11-062019-10-28Hanmi Pharm Ind Co LtdLiquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
MX360317B (en)*2012-12-212018-10-29Sanofi SaFunctionalized exendin-4 derivatives.
CN105324397B (en)2013-03-142020-01-14印第安纳大学研究及科技有限公司Insulin-incretin conjugates
EP2976325B1 (en)2013-03-212017-03-01Sanofi-Aventis Deutschland GmbHSynthesis of cyclic imide containing peptide products
HK1219477A1 (en)2013-03-212017-04-07Sanofi-Aventis Deutschland GmbhSynthesis of hydantoin containing peptide products
WO2014161835A1 (en)2013-04-032014-10-09SanofiModified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
LT3004155T (en)*2013-05-282021-12-27Takeda Pharmaceutical Company Limited PEPTIDE COMPOUND
WO2015035419A1 (en)*2013-09-092015-03-12Hoffmann-La Roche Inc.Dosages of gip/glp-1 co-agonist peptides for human administration
US9988429B2 (en)2013-10-172018-06-05Zealand Pharma A/SGlucagon analogues
AU2014336098B2 (en)2013-10-172018-05-10Boehringer Ingelheim International GmbhAcylated glucagon analogues
WO2015067716A1 (en)2013-11-062015-05-14Zealand Pharma A/SGlucagon-glp-1-gip triple agonist compounds
WO2015067715A2 (en)2013-11-062015-05-14Zealand Pharma A/SGip-glp-1 dual agonist compounds and methods
US9339482B2 (en)2013-11-222016-05-17Regents Of The University Of MinnesotaMethods to treat dysregulated blood glucose disorders
WO2015086728A1 (en)2013-12-132015-06-18SanofiExendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080149A1 (en)2013-12-132016-10-19SanofiDual glp-1/glucagon receptor agonists
WO2015086729A1 (en)2013-12-132015-06-18SanofiDual glp-1/gip receptor agonists
EP3080152A1 (en)2013-12-132016-10-19SanofiNon-acylated exendin-4 peptide analogues
AR098616A1 (en)2013-12-182016-06-01Lilly Co Eli PEPTIDE FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA
TW201625668A (en)2014-04-072016-07-16賽諾菲公司Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en)2014-04-072016-07-16賽諾菲公司Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en)2014-04-072016-07-16賽諾菲公司Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
US9932381B2 (en)2014-06-182018-04-03SanofiExendin-4 derivatives as selective glucagon receptor agonists
GB2528436A (en)*2014-07-152016-01-27Lancaster Univ Business Entpr LtdTreatment of neurological diseases
CN105504009B (en)*2014-09-242018-10-09中国科学院大连化学物理研究所A kind of polypeptide and its application derived from deer's sinew with DPP-IV inhibitory activity
JP6657230B2 (en)2014-09-242020-03-04インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Incretin-insulin conjugate
CN105504008B (en)*2014-09-242018-09-21中国科学院大连化学物理研究所A kind of deer peptide and its application with DPP-IV inhibitory activity
CN105504010B (en)*2014-09-242018-09-21中国科学院大连化学物理研究所A kind of polypeptide and its application with DPP-IV inhibitory activity
CN105440102B (en)*2014-09-242018-09-25中国科学院大连化学物理研究所A kind of polypeptide and its application derived from deerskin with DPP-IV inhibitory activity
CN105504011B (en)*2014-09-242018-09-25中国科学院大连化学物理研究所A kind of polypeptide with DPP-IV inhibitory activity and its application in preparing hypoglycemic drug
US20160114000A1 (en)2014-10-242016-04-28Merck Sharp & Dohme Corp.Co-agonists of the glucagon and glp-1 receptors
EP3212218B1 (en)*2014-10-292021-06-30Zealand Pharma A/SGip agonist compounds and methods
KR102418477B1 (en)2014-12-302022-07-08한미약품 주식회사Gluagon Derivatives
JOP20200119A1 (en)2015-01-092017-06-16Lilly Co EliGip and glp-1 co-agonist compounds
US10336802B2 (en)2015-04-162019-07-02Zealand Pharma A/SAcylated glucagon analogue
AR105319A1 (en)2015-06-052017-09-27Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
WO2016198624A1 (en)2015-06-122016-12-15SanofiExendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI783244B (en)*2015-06-222022-11-11美商美國禮來大藥廠Glucagon and glp-1 co-agonist compounds
TW201706291A (en)2015-07-102017-02-16賽諾菲公司New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
UA127495C2 (en)2015-12-232023-09-13Амджен Інк. ISOLATED ANTIGEN-BINDING PROTEIN THAT SPECIFICALLY BINDS TO HUMAN GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
CN115920077B (en)*2015-12-312025-07-04韩美药品株式会社 Long-acting conjugate of glucagon/GLP-1/GIP receptor triple agonist
KR20220150416A (en)*2016-03-102022-11-10메디뮨 리미티드Glucagon and glp-1 co-agonists for the treatment of obesity
WO2017160669A1 (en)*2016-03-182017-09-21Merck Sharp & Dohme Corp.Insulin-incretin conjugates
EP3463423A4 (en)*2016-06-022019-05-08Indiana University Research & Technology Corporation GLUCAGON-T3 CONJUGATES
WO2017210100A1 (en)*2016-06-022017-12-07Indiana University Research And Technology CorporationGlucagon-like peptide-1-t3 conjugates
GB201620611D0 (en)2016-12-052017-01-18Univ Of LancasterTreatment of neurological diseases
US11285180B2 (en)2016-12-062022-03-29Inserm (Institut National De La Sante Et De La Recherche Medicale)Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20190177A1 (en)2017-01-172019-07-16Amgen IncMethod of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
US20200138966A1 (en)*2017-01-272020-05-07Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical CollegeBifunctional small peptide for autoimmune diabetes
CN106986924A (en)*2017-03-232017-07-28中国药科大学Oxyntomodulin（OXM）Analog and its application
JOP20180028A1 (en)2017-03-312019-01-30Takeda Pharmaceuticals Co Polypeptide compound
WO2018213151A1 (en)2017-05-182018-11-22Merck Sharp & Dohme Corp.Pharmaceutical formulation comprising incretin-insulin conjugates
CA3064510A1 (en)2017-05-312018-12-06University Of CopenhagenLong-acting gip peptide analogues
CA3062194A1 (en)2017-06-202018-12-27Amgen Inc.Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
CN108210988A (en)*2018-03-082018-06-29武汉职业技术学院A kind of fish skin collagen prepares the new process of medical sthptic sponge
MY205468A (en)*2018-03-232024-10-22Carmot Therapeutics IncModulators of g-protein coupled receptors
MX2020011427A (en)2018-05-042020-12-07Novo Nordisk AsGip derivatives and uses thereof.
TWI705820B (en)2018-06-222020-10-01美商美國禮來大藥廠Gip/glp1 agonist compositions
CN111825758B (en)*2019-04-192024-11-22上海翰森生物医药科技有限公司 GLP-1 and GIP co-agonist compounds
CN111944055B (en)*2019-05-162022-08-02浙江道尔生物科技有限公司Fusion protein for treating metabolic diseases
EP4015528A4 (en)*2019-08-132023-09-20Anygen Co., Ltd. EXENATIDE ANALOG AND USE THEREOF
TWI795698B (en)*2019-12-182023-03-11美商美國禮來大藥廠Incretin analogs and uses thereof
TW202216746A (en)*2020-06-222022-05-01印度商太陽製藥工業有限公司Long acting glp-1/gip dual agonists
CA3184723A1 (en)*2020-07-222022-01-27Patrick J. KNERRGlp-1 and gip receptor co-agonists
AU2022272251A1 (en)2021-05-132023-11-16Carmot Therapeutics Inc.Modulators of g-protein coupled receptors
WO2023016346A1 (en)*2021-08-102023-02-16南京明德新药研发有限公司Polypeptide compound containing lactam bridge
AU2022400245A1 (en)2021-12-022024-05-30Københavns UniversitetPeptide-drug conjugates for treatment of neurodegenerative diseases

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4450150A (en)1973-05-171984-05-22Arthur D. Little, Inc.Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4275152A (en)1977-02-031981-06-23Eastman Kodak CompanyHydrolysis of protein-bound cholesterol esters
PT83613B (en)1985-10-281988-11-21Lilly Co EliProcess for the selective chemical removal of a protein amino-terminal residue
EP0272253A4 (en)1986-03-071990-02-05Massachusetts Inst TechnologyMethod for enhancing glycoprotein stability.
IN165717B (en)1986-08-071989-12-23Battelle Memorial Institute
CA2047191A1 (en)1989-02-171990-08-18Hendrik M. GeysenMethod for the use and synthesis of peptides
JP3262329B2 (en)1990-01-242002-03-04アイ． バックレイ，ダグラス GLP-1 analog useful for the treatment of diabetes
US5545618A (en)1990-01-241996-08-13Buckley; Douglas I.GLP-1 analogs useful for diabetes treatment
CA2024855C (en)1990-09-071997-12-09Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) LteeProcess and intermediates for producing glucagon
JPH04145099A (en)1990-10-051992-05-19Sanwa Kagaku Kenkyusho Co LtdPolypeptide derivative having gip-like activity and use thereof
US5510459A (en)1991-01-171996-04-23Zymogenetics, Inc.Glucagon antagonists
JP3266311B2 (en)1991-05-022002-03-18生化学工業株式会社 Novel polypeptide and anti-HIV agent using the same
US5359030A (en)1993-05-101994-10-25Protein Delivery, Inc.Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5480867A (en)*1993-12-291996-01-02The Rockefeller UniversityGlucagon analogs with serine replacements
US5512549A (en)1994-10-181996-04-30Eli Lilly And CompanyGlucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en)1995-03-171999-02-09Novo Nordisk A/SPeptide derivatives
DE19530865A1 (en)1995-08-221997-02-27Michael Dr Med Nauck Active ingredient and agent for parenteral nutrition
CA2243718A1 (en)1996-02-061997-08-14Eli Lilly And CompanyDiabetes therapy
KR100600457B1 (en)1996-06-052006-07-13로셰 디아그노스틱스 게엠베하 Exendin analogs, preparation methods thereof, and pharmaceuticals containing the same
EP0932614A1 (en)1996-09-091999-08-04Zealand Pharmaceuticals A/SPeptide prodrugs containing an alpha-hydroxyacid linker
UA65549C2 (en)1996-11-052004-04-15Елі Ліллі Енд КомпаніUse of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
AU5518798A (en)1996-12-031998-06-29Trustees Of Boston UniversitySpecific antagonists for glucose-dependent insulinotropic polypeptide (gip)
AU2546399A (en)1998-02-101999-08-30Yoshitomi Pharmaceutical Industries, Ltd.Preparations with controlled release
EP1950223A3 (en)1998-03-092009-05-13Zealand Pharma A/SPharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
DE19828113A1 (en)1998-06-242000-01-05Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
US20030236190A1 (en)1998-09-022003-12-25Renuka PillutlaIsulin and IGF-1 receptor agonists and antagonists
EP1119625B1 (en)1998-10-072005-06-29Medical College Of Georgia Research Institute, Inc.Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
GB2344287A (en)1998-12-032000-06-07Ferring BvControlled release pharmaceutical formulation
ES2230912T3 (en)1998-12-072005-05-01Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. GLP-1 ANALOG.
EP1147094A1 (en)1999-01-152001-10-24Novo Nordisk A/SNon-peptide glp-1 agonists
GB0404124D0 (en)2004-02-252004-03-31Univ UlsterAntagonists of GIP
AU3441400A (en)1999-03-292000-10-16Uutech LimitedPeptide
WO2000069911A1 (en)1999-05-172000-11-23Conjuchem, Inc.Long lasting insulinotropic peptides
WO2001081919A2 (en)2000-04-272001-11-01Bionebraska, Inc.Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
US6677136B2 (en)2000-05-032004-01-13Amgen Inc.Glucagon antagonists
JP2004503565A (en)2000-06-142004-02-05サイトヴァックス・バイオテクノロジーズ・インコーポレーテッド Use of coiled-coil structural scaffolds to produce structure-specific peptides
ATE424413T1 (en)2000-06-162009-03-15Lilly Co Eli ANALOGUE OF GLUCAGONE-LIKE PEPTIDE-1
CA2417100A1 (en)2000-08-022002-02-07Theratechnologies Inc.Modified peptides with increased potency
US6262062B1 (en)2000-08-152001-07-17Cpd, LlcMethod of treating the syndrome of coronary heart disease risk factors in humans
US20020045572A1 (en)2000-08-152002-04-18Cpd, LlcMethod of treating the syndrome of type 2 diabetes in humans
US6528520B2 (en)2000-08-152003-03-04Cpd, LlcMethod of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en)2000-08-152005-01-25Cpd, LlcMethod of treating the syndrome of lipodystrophy
WO2002026265A2 (en)2000-09-292002-04-04Schering CorporationPegylated interleukin-10
EP1351984A2 (en)2000-12-132003-10-15Eli Lilly And CompanyAmidated glucagon-like peptide-1
ATE408414T1 (en)2001-07-312008-10-15Us Gov Health & Human Serv GLP 1 EXENDIN 4 PEPTIDE ANALOGUES AND THEIR USES
WO2003014318A2 (en)2001-08-082003-02-20Genzyme CorporationMethods for treating diabetes and other blood sugar disorders
JP2005508895A (en)2001-08-282005-04-07イーライ・リリー・アンド・カンパニー Premix of GLP-1 and basal insulin
GB0121709D0 (en)2001-09-072001-10-31Imp College Innovations LtdFood inhibition agent
AR036711A1 (en)2001-10-052004-09-29Bayer Corp PEPTIDES THAT ACT AS GLON-RECEPTOR AGONISTS AND AS GLUCAGON RECEPTOR ANTAGONISTS AND THEIR PHARMACOLOGICAL USE METHODS
US7041646B2 (en)2001-10-052006-05-09Bayer Pharmaceuticals CorporationMethods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
HUP0700151A2 (en)2001-10-182007-05-29Bristol Myers Squibb CoHuman glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
MXPA04003569A (en)2001-10-192004-07-23Lilly Co EliBiphasic mixtures of glp-1 and insulin.
EP1461069A2 (en)2001-12-292004-09-29Novo Nordisk A/SCombined use of a glp-1 compound and another drug for treating dyslipidemia
EP1585959A4 (en)2002-01-082007-11-14Lilly Co EliExtended glucagon-like peptide-1 analogs
US20030232761A1 (en)2002-03-282003-12-18Hinke Simon A.Novel analogues of glucose-dependent insulinotropic polypeptide
US20060252916A1 (en)2002-06-042006-11-09Eli Lilly And CompanyModified glucagon-like peptide-1 analogs
JP2006502100A (en)2002-06-112006-01-19エーザイ株式会社 Use of a compound having GIP activity for the treatment of disorders associated with abnormal loss of cells and / or for the treatment of obesity
CA2489323A1 (en)2002-06-152003-12-24Enteromed, Inc.Treatment of non-alcoholic fatty liver disease
EP1539210A4 (en)2002-09-062006-06-07Bayer Pharmaceuticals CorpModified glp-1 receptor agonists and their pharmacological methods of use
ATE458534T1 (en)2002-10-042010-03-15Microchips Inc MEDICAL DEVICE FOR CONTROLLED DRUG ADMINISTRATION AND CARDIAC MONITORING AND/OR HEART STIMULATION
US7192922B2 (en)2002-11-192007-03-20Allegheny-Singer Research InstituteMethod of treating left ventricular dysfunction
US7329990B2 (en)2002-12-272008-02-12Lg Electronics Inc.Plasma display panel having different sized electrodes and/or gaps between electrodes
JP2006524039A (en)2003-01-092006-10-26マクロジェニクス，インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
US20050059605A1 (en)2003-01-312005-03-17Krishna PeriChemically modified metabolites of regulatory peptides and methods of producing and using same
WO2004078777A2 (en)2003-03-042004-09-16Biorexis Pharmaceutical CorporationDipeptidyl-peptidase protected proteins
KR100733940B1 (en)2003-03-192007-06-29일라이 릴리 앤드 캄파니 LP-1 Compound Connected with Polyethylene Glycol
EP1620118B1 (en)2003-04-082014-06-18Yeda Research And Development Co., Ltd.Reversible pegylated drugs
TWI353991B (en)2003-05-062011-12-11Syntonix Pharmaceuticals IncImmunoglobulin chimeric monomer-dimer hybrids
ES2383752T3 (en)2003-05-152012-06-26Trustees Of Tufts College GLP-1 stable analogs
WO2004105790A1 (en)2003-06-032004-12-09Novo Nordisk A/SStabilized pharmaceutical peptide compositions
WO2004105781A2 (en)2003-06-032004-12-09Novo Nordisk A/SStabilized pharmaceutical peptide compositions
AU2004251145C1 (en)2003-06-122011-04-14Eli Lilly And CompanyGLP-1 analog fusion proteins
US20050124550A1 (en)2003-06-182005-06-09Peri Krishna G.Compounds that modulate the glucagon response and uses thereof
BR122019021416A2 (en)2003-09-192019-12-21
US7364875B2 (en)2003-10-302008-04-29Cresent Innovations, Inc.Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
AU2004298424A1 (en)2003-12-182005-06-30Novo Nordisk A/SNovel GLP-1 compounds
US20060286129A1 (en)2003-12-192006-12-21Emisphere Technologies, Inc.Oral GLP-1 formulations
US20080318837A1 (en)2003-12-262008-12-25Nastech Pharmaceutical Company Inc.Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7442682B2 (en)2004-10-192008-10-28Nitto Denko CorporationTransepithelial delivery of peptides with incretin hormone activities
US7327408B1 (en)2004-11-152008-02-05Lightmaster Systems, Inc.Illuminator that generates linearly polarized light for microdisplay based light engine
KR20070115947A (en)*2005-02-112007-12-06아밀린 파마슈티칼스, 인크. JP analogs and hybrid polypeptides with selectable properties
US8263545B2 (en)2005-02-112012-09-11Amylin Pharmaceuticals, Inc.GIP analog and hybrid polypeptides with selectable properties
WO2006097536A2 (en)2005-03-182006-09-21Novo Nordisk A/SDimeric peptide agonists of the glp-1 receptor
WO2006121904A1 (en)2005-05-062006-11-16Bayer Pharmaceuticals CorporationGlucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
BRPI0609676A2 (en)2005-05-132011-10-18Lilly Co Eli compound of pegylated glp-1, and use thereof
KR101349808B1 (en)2005-06-132014-02-13임페리얼 이노베이션스 리미티드Novel compounds and their effects on feeding behaviour
EP2330124B1 (en)2005-08-112015-02-25Amylin Pharmaceuticals, LLCHybrid polypeptides with selectable properties
EP1937716A2 (en)2005-09-082008-07-02Uutech LimitedAnalogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
EP1943274A2 (en)2005-09-082008-07-16Uutech LimitedTreatment of diabetes related obesity
US7846445B2 (en)2005-09-272010-12-07Amunix Operating, Inc.Methods for production of unstructured recombinant polymers and uses thereof
CA2628241C (en)2005-11-072016-02-02Indiana University Research And Technology CorporationGlucagon analogs exhibiting physiological solubility and stability
US7928058B2 (en)2006-02-222011-04-19Merck Sharp & Dohme Corp.Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
EP1996224B1 (en)2006-03-152012-11-07Novo Nordisk A/SMixtures of amylin and insulin
EP2004238A2 (en)2006-03-212008-12-24Amylin Pharmaceuticals, Inc.Peptide-peptidase inhibitor conjugates and methods of using same
US8288339B2 (en)2006-04-202012-10-16Amgen Inc.GLP-1 compounds
EP2020989A2 (en)2006-05-152009-02-11Wisconsin Allumni Research FoundationPulmonary delivery of 1,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (en)2006-06-072008-09-05Sapelem Soc Par Actions Simpli LOAD HANDLING APPARATUS
WO2008022015A2 (en)2006-08-112008-02-21Trustees Of Tufts CollegeRetro-inverso incretin analogues, and methods of use thereof
CA2660835A1 (en)2006-08-172008-02-21Amylin Pharmaceuticals, Inc.Dpp-iv resistant gip hybrid polypeptides with selectable propperties
US20090318353A1 (en)2006-08-252009-12-24Novo Nordisk A/SAcylated Exendin-4 Compounds
CA2663083A1 (en)2006-09-082008-03-13Ambrx, Inc.Modified human plasma polypeptide or fc scaffolds and their uses
WO2008076933A2 (en)2006-12-142008-06-26Bolder Biotechnology, Inc.Long acting proteins and peptides and methods of making and using the same
SG177953A1 (en)2007-01-052012-02-28Univ Indiana Res & Tech CorpGlucagon analogs exhibiting enhanced solubility in physiological ph buffers
KR20090119876A (en)2007-02-152009-11-20인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon / LPL-1 Receptor Co-Analyst
NZ580700A (en)2007-04-192012-01-12Dong A Pharm Co LtdA biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
DK2158214T3 (en)2007-06-152011-12-05Zealand Pharma As Glucagon analogues
EP2185701A4 (en)2007-08-152011-03-02Amunix Operating IncCompositions and methods for modifying properties of biologically active polypeptides
JP2010538049A (en)2007-09-052010-12-09ノボ・ノルデイスク・エー／エス Cleaved GLP-1 derivatives and therapeutic uses thereof
EP2679597A1 (en)2007-09-052014-01-01Novo Nordisk A/SGlucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009035540A2 (en)2007-09-072009-03-19Ipsen Pharma S.A.S.Analogues of exendin-4 and exendin-3
EP2036539A1 (en)2007-09-112009-03-18Novo Nordisk A/SStable formulations of amylin and its analogues
EP2036923A1 (en)2007-09-112009-03-18Novo Nordisk A/SImproved derivates of amylin
CN101854948A (en)2007-09-112010-10-06诺沃-诺迪斯克有限公司 Combination containing amylin and long-acting insulin
EP2214691B1 (en)2007-10-302015-09-30Indiana University Research and Technology CorporationCompounds exhibiting glucagon antagonist and glp-1 agonist activity
WO2009058662A2 (en)2007-10-302009-05-07Indiana University Research And Technology CorporationGlucagon antagonists
US20090181037A1 (en)2007-11-022009-07-16George HeavnerSemi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
WO2009099763A1 (en)*2008-01-302009-08-13Indiana University Research And Technology CorporationEster-based peptide prodrugs
EP3981761A3 (en)2008-02-012022-08-24Ascendis Pharma A/SIntermediates for prodrugs
CA2852177A1 (en)*2008-06-172009-12-23Indiana University Research And Technology CorporationGlucagon/glp-1 receptor co-agonists
WO2009155257A1 (en)2008-06-172009-12-23Indiana University Research And Technology CorporationGlucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
CL2009001424A1 (en)2008-06-172010-04-30Univ Indiana Res & Tech Corp Glucagon-like peptide; dimer comprising two of said peptides; pharmaceutical composition comprising it; and its use to treat diabetes or induce weight loss.
PE20100056A1 (en)2008-06-172010-01-26Univ Indiana Res & Tech Corp GLUCAGON ANALOGS AS GIP AGONISTS
EP2376098A4 (en)2008-12-192014-06-11Univ Indiana Res & Tech Corp MEDICINAL AGENTS RELATED BY DIPEPTIDES
CN102325539A (en)2008-12-192012-01-18印第安纳大学研究及科技有限公司 Amide-based glucagon superfamily peptide prodrugs
WO2010096052A1 (en)2009-02-192010-08-26Merck Sharp & Dohme Corp.Oxyntomodulin analogs
US9044808B2 (en)2009-03-032015-06-02The Johns Hopkins UniversitySystem and method for precision transport, positioning, and assembling of longitudinal nano-structures
PE20120914A1 (en)2009-06-162012-08-22Univ Indiana Res & Tech Corp GIP RECEIVER ACTIVE GLUCAGON COMPOUNDS
EP2512503A4 (en)2009-12-182013-08-21Univ Indiana Res & Tech Corp GLUCAGON / GLP-I RECEPTOR CO-AGONISTS
AR079344A1 (en)2009-12-222012-01-18Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
JO2976B1 (en)2009-12-222016-03-15ايلي ليلي اند كومبانيOxyntomodulin peptide analogue ‎
IN2012DN06437A (en)2010-01-272015-10-09Univ Indiana Res & Tech Corp
AR080592A1 (en)2010-03-262012-04-18Lilly Co Eli PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
MX2012013005A (en)*2010-05-132013-02-26Univ Indiana Res & Tech CorpGlucagon superfamily peptides exhibiting g protein-coupled receptor activity.
RU2604067C2 (en)2010-05-132016-12-10Индиана Юниверсити Рисерч Энд Текнолоджи КорпорейшнGlucagon superfamily peptides exhibiting nuclear hormone receptor activity
JP2013540102A (en)*2010-06-242013-10-31インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Peptide prodrugs of the glucagon superfamily modified via amide bonds
WO2011163473A1 (en)2010-06-252011-12-29Indiana University Research And Technology CorporationGlucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
EP2654774A4 (en)*2010-12-222015-07-01Marcadia Biotech IncMethods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
PH12013501215A1 (en)*2010-12-222013-11-18Univ Indiana Res & Tech CorpGlucagon analogs exhibiting gip receptor activity
US9044108B1 (en)2012-05-182015-06-02Roy G. KonrathCombination storage and display system

Also Published As

Publication numberPublication date
US8551946B2 (en)2013-10-08
EP2528618A1 (en)2012-12-05
JP2013518115A (en)2013-05-20
WO2011094337A1 (en)2011-08-04
BR112012018585A2 (en)2017-01-10
CA2788304A1 (en)2011-08-04
RU2012136450A (en)2014-03-10
MX2012008603A (en)2013-01-25
US9487571B2 (en)2016-11-08
WO2011094337A8 (en)2012-08-16
EP2528618A4 (en)2015-05-27
US20120322725A1 (en)2012-12-20
CN102834108A (en)2012-12-19
US20140107021A1 (en)2014-04-17
KR20120123443A (en)2012-11-08
JP2016183177A (en)2016-10-20

Similar Documents

PublicationPublication DateTitle
IN2012DN06437A (en)
GEP20176629B (en)Glucagon/glp-1 receptor co-agonists
PH12017500761A1 (en)Co-agonists of glucagon and glp-1 receptors
GT201200263A (en) "NEW PEPTIDES AND METHODS FOR PREPARATION AND USE"
ECSP10010684A (en) MIXED AGONISTS, BASED ON GIP FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY.
MX2012006406A (en)Multispecific antibodies, antibody analogs, compositions, and methods.
MX345245B (en)Engineered polypeptides having enhanced duration of action.
CL2012002031A1 (en) Pharmaceutical composition containing at least one fgf-21 compound (fibroblast growth factor 21) and at least one glp-1r agonist (glucagon-like peptide 1 receptor); and its use to prepare a medicament for the treatment of at least one metabolic syndrome and / or atherosclerosis in a patient.
WO2012112690A3 (en)Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
NZ594056A (en)New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
WO2011075393A3 (en)Glucagon/glp-1 receptor co-agonists
PH12013501244A1 (en)A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
CL2008002111A1 (en) COMPOUNDS DERIVED FROM PIRIDONA, AGONISTS OF THE RECEPTOR COUPLED TO PROTEIN G GPR119; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DIABETES, METABOLIC SYNDROME, CANCER, AMONG OTHERS.
EA201300016A1 (en) HUMAN ANTIBODY CONJUGATES AGAINST TISSUE FACTOR WITH DRUGS
CL2012003026A1 (en) Pharmaceutical composition comprising pioglitazone and linagliptin; preparation procedure; Use in the treatment of type 2 diabetes or obesity.
NZ700296A (en)Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
EA201190017A1 (en) AMINO ETHER DERIVATIVES OF ALKALOIDS AND THEIR MEDICAL COMPOSITIONS
JO2831B1 (en)Quinuclidine Carbonate Derivatives and Medicinal Composition Thereof
ES2445846R1 (en) A pharmaceutical combination composition and its use to prepare a medicament for the treatment of type 1 diabetes and metabolic disorders
BR112012027545A8 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF THE PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND
WO2011044452A3 (en)Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
NZ592049A (en)Compositions and methods for the treatment of bowel diseases with granulated mesalamine
EA201390653A1 (en) AA ANTAGONISTS AS AMPLIFIERS OF COGNITIVE AND MOTOR FUNCTIONS
AU2010353685A8 (en)Novel glucagon like peptide analogs, composition, and method of use
WO2014059384A3 (en)ICAM-1 TARGETING ELPs
[8]ページ先頭
©2009-2025 Movatter.jp